Burden of Respiratory Syncytial Virus (RSV) Infection Among Adults in Nursing and Care Homes: A Systematic Review.
adults
and care home
burden
infection
nursing
respiratory syncytial virus
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
20
08
2024
received:
17
04
2024
accepted:
29
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
ppublish
Résumé
Older adults in nursing and care homes (NCHs) are vulnerable to severe respiratory syncytial virus (RSV) infection, hospitalization, and death. This study aimed to gather data on RSV disease among older adults in NCHs and identify reported risk factors for RSV hospitalization and case fatality. The study protocol was registered in PROSPERO (CRD42022371908). We searched MEDLINE, EMBASE, and Global Health databases to identify articles published between 2000 and 2023. Observational and experimental studies conducted among older adults in NCHs requiring assistive care and reporting RSV illness were included and relevant data were extracted. Of 18,690 studies screened, 32 were selected for full-text review, and 20 were included. Overall, the number of NCH residents ranged from 42 to 1459 with a mean age between 67.6 and 85 years. Attack rates ranged from 6.7% to 47.6% and annual incidence ranged from 0.5% to 14%. Case fatality rates ranged from 7.7% to 23.1%. We found similar annual incidence rates of RSV-positive acute respiratory infection (ARI) of 4582 (95% CI: 3259-6264) and 4785 (95% CI: 2258-10,141) per 100,000 reported in two studies. Annual incidence rate of RSV-positive lower respiratory tract infection was 3040 (95% CI: 1986-4454) cases per 100,000 adults. Annual RSV-ARI hospital admission rates were between 600 (95% CI: 190-10,000) and 1104 (95% CI: 350-1930) per 100,000 person-years. Among all RSV disease cases, commonly reported chronic medical conditions included chronic obstructive pulmonary disease (COPD), heart failure, ischemic heart disease, coronary artery disease, hypertension, diabetes, kidney dysfunction, cerebrovascular accident, malignancies, dementia, and those with a Charlson comorbidity score > 6.5. Data on RSV infection among NCH residents are limited and largely heterogeneous but document a high risk of illness, frequent hospitalization, and high mortality. Preventive interventions, such as vaccination, should be considered for this high-risk population. Nationally representative epidemiologic studies and NCH-based viral pathogen surveillance could more precisely assess the burden on NCH residents.
Sections du résumé
BACKGROUND
BACKGROUND
Older adults in nursing and care homes (NCHs) are vulnerable to severe respiratory syncytial virus (RSV) infection, hospitalization, and death. This study aimed to gather data on RSV disease among older adults in NCHs and identify reported risk factors for RSV hospitalization and case fatality.
METHODS
METHODS
The study protocol was registered in PROSPERO (CRD42022371908). We searched MEDLINE, EMBASE, and Global Health databases to identify articles published between 2000 and 2023. Observational and experimental studies conducted among older adults in NCHs requiring assistive care and reporting RSV illness were included and relevant data were extracted.
RESULTS
RESULTS
Of 18,690 studies screened, 32 were selected for full-text review, and 20 were included. Overall, the number of NCH residents ranged from 42 to 1459 with a mean age between 67.6 and 85 years. Attack rates ranged from 6.7% to 47.6% and annual incidence ranged from 0.5% to 14%. Case fatality rates ranged from 7.7% to 23.1%. We found similar annual incidence rates of RSV-positive acute respiratory infection (ARI) of 4582 (95% CI: 3259-6264) and 4785 (95% CI: 2258-10,141) per 100,000 reported in two studies. Annual incidence rate of RSV-positive lower respiratory tract infection was 3040 (95% CI: 1986-4454) cases per 100,000 adults. Annual RSV-ARI hospital admission rates were between 600 (95% CI: 190-10,000) and 1104 (95% CI: 350-1930) per 100,000 person-years. Among all RSV disease cases, commonly reported chronic medical conditions included chronic obstructive pulmonary disease (COPD), heart failure, ischemic heart disease, coronary artery disease, hypertension, diabetes, kidney dysfunction, cerebrovascular accident, malignancies, dementia, and those with a Charlson comorbidity score > 6.5.
CONCLUSION
CONCLUSIONS
Data on RSV infection among NCH residents are limited and largely heterogeneous but document a high risk of illness, frequent hospitalization, and high mortality. Preventive interventions, such as vaccination, should be considered for this high-risk population. Nationally representative epidemiologic studies and NCH-based viral pathogen surveillance could more precisely assess the burden on NCH residents.
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70008Subventions
Organisme : Pfizer
Informations de copyright
© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
J. M. McLaughlin, F. Khan, E. Begier, D. L. Swerdlow, L. Jodar, and A. R. Falsey, “Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta‐Analysis,” Open Forum Infectious Diseases 9, no. 7 (2022): ofac300.
J. Ramirez, R. Carrico, A. Wilde, et al., “Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT–PCR,” Infectious Disease and Therapy 12, no. 6 (2023): 1593–1603.
C. Onwuchekwa, L. M. Moreo, S. Menon, et al., “Under‐Ascertainment of Respiratory Syncytial Virus Infection in Adults due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta‐Analysis,” Journal of Infectious Diseases 228 (2023): 173–184.
R. O. Barker, B. Hanratty, A. Kingston, S. E. Ramsay, and F. E. Matthews, “Changes in Health and Functioning of Care Home Residents Over Two Decades: What Can We Learn From Population‐Based Studies?” Age and Ageing 50, no. 3 (2021): 921–927.
A. T. Borchers, C. Chang, M. E. Gershwin, and L. J. Gershwin, “Respiratory Syncytial Virus‐‐A Comprehensive Review,” Clinical Reviews in Allergy and Immunology 45, no. 3 (2013): 331–379.
N. Haber, “Respiratory Syncytial Virus Infection in Elderly Adults,” Médecine et Maladies Infectieuses 48, no. 6 (2018): 377–382.
H. H. Nam and M. G. Ison, “Respiratory Syncytial Virus Infection in Adults,” BMJ 366 (2019): l5021.
M. J. Page, J. E. McKenzie, P. M. Bossuyt, et al., “The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews,” BMJ 372 (2021): n71.
R. Osei‐Yeboah, P. Spreeuwenberg, M. Del Riccio, et al., “Estimation of the Number of Respiratory Syncytial Virus–Associated Hospitalizations in Adults in the European Union,” Journal of Infectious Diseases 228 (2023): 1539–1548.
Y. Li, D. Kulkarni, E. Begier, et al., “Adjusting for Case Under‐Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High‐Income Countries: A Systematic Review and Modelling Study,” Infectious Disease and Therapy 12, no. 4 (2023): 1137–1149.
S. Narejos Pérez, J. M. Ramón Torrell, A. Põder, et al., “Respiratory Syncytial Virus Disease Burden in Community‐Dwelling and Long‐Term Care Facility Older Adults in Europe and the United States: A Prospective Study,” Open Forum Infectious Diseases 10, no. 4 (2023): ofad111.
G. Akner, “Analysis of Multimorbidity in Individual Elderly Nursing Home Residents. Development of a Multimorbidity Matrix,” Archives of Gerontology and Geriatrics 49, no. 3 (2009): 413–419.
K. L. Moore, W. J. Boscardin, M. A. Steinman, and J. B. Schwartz, “Patterns of Chronic Co‐Morbid Medical Conditions in Older Residents of U.S. Nursing Homes: Differences Between the Sexes and Across the Agespan,” Journal of Nutrition, Health & Aging 18, no. 4 (2014): 429–436.
J. P. T. Higgins, D. G. Altman, P. C. Gotzsche, et al., “The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials,” BMJ 343, no. oct18 2 (2011): d5928‐d.
ROBINS‐E Development Group, Higgins JM, Rooney A, et al., “Risk of Bias in Non‐Randomized Studies ‐ of Exposure (ROBINS‐E). Launch Version, 20 June 2023,” (2023), https://www.riskofbias.info/welcome/robins‐e‐tool.
L. A. McGuinness and J. P. T. Higgins, “Risk‐of‐Bias Visualization (Robvis): An R Package and Shiny Web App for Visualizing Risk‐of‐Bias Assessments,” Research Synthesis Methods 12, no. 1 (2021): 55–61.
N. Barrett, L. Bailey, F. Ford, et al., “Respiratory Syncytial Virus Outbreak in a Veterans Affairs Long‐Term Care Facility,” Infectious Diseases in Clinical Practice 28, no. 4 (2020): 200–203.
L. B. Caram, J. Chen, E. W. Taggart, et al., “Respiratory Syncytial Virus Outbreak in a Long‐Term Care Facility Detected Using Reverse Transcriptase Polymerase Chain Reaction: An Argument for Real‐Time Detection Methods,” Journal of the American Geriatrics Society 57, no. 3 (2009): 482–485.
S. S. Spires, H. K. Talbot, C. A. Pope, and T. R. Talbot, “Paramyxovirus Outbreak in a Long‐Term Care Facility: The Challenges of Implementing Infection Control Practices in a Congregate Setting,” Infection Control & Hospital Epidemiology 38, no. 4 (2017): 399–404.
M. M. Checovich, S. Barlow, P. Shult, E. Reisdorf, and J. L. Temte, “Evaluation of Viruses Associated With Acute Respiratory Infections in Long‐Term Care Facilities Using a Novel Method: Wisconsin, 2016–2019,” Journal of the American Medical Directors Association 21, no. 1 (2020): 29–33.
S. E. Ellis, C. S. Coffey, E. F. Mitchel, R. S. Dittus, and M. R. Griffin, “Influenza and Respiratory Syncytial Virus Associated Morbidity and Mortality in the Nursing Home Population,” Journal of the American Geriatrics Society 51, no. 6 (2003): 761–767.
A. R. Falsey, G. E. Dallal, M. A. Formica, et al., “Long‐Term Care Facilities: A Cornucopia of Viral Pathogens,” Journal of the American Geriatrics Society 56, no. 7 (2008): 1281–1285.
J. E. McElhaney, S. Gravenstein, S. K. Cole, et al., “A Placebo‐Controlled Trial of a Proprietary Extract of North American Ginseng (CVT‐E002) to Prevent Acute Respiratory Illness in Institutionalized Older Adults,” Journal of the American Geriatrics Society 52, no. 1 (2004): 13–19.
C. A. O'Neil, L. Kim, M. M. Prill, et al., “Respiratory Viral Surveillance of Healthcare Personnel and Patients at an Adult Long‐Term Care Facility,” Infection Control & Hospital Epidemiology 40, no. 11 (2019): 1309–1312.
J. D. Diaz‐Decaro, B. Launer, J. A. McKinnell, et al., “Bayesian Evidence and Epidemiological Implications of Environmental Contamination From Acute Respiratory Infection in Long‐Term Care Facilities,” Epidemiology and Infection 146, no. 7 (2018): 832–838.
M. Loeb, A. McGeer, M. McArthur, R. W. Peeling, M. Petric, and A. E. Simor, “Surveillance for Outbreaks of Respiratory Tract Infections in Nursing Homes,” CMAJ 162, no. 8 (2000): 1133–1137.
J. Johnstone, R. Parsons, F. Botelho, et al., “Immune Biomarkers Predictive of Respiratory Viral Infection in Elderly Nursing Home Residents,” PLoS ONE 9, no. 9 (2014): e108481.
I. Doi, N. Nagata, H. Tsukagoshi, et al., “An Outbreak of Acute Respiratory Infections due to Human Respiratory Syncytial Virus in a Nursing Home for the Elderly in Ibaraki, Japan, 2014,” Japanese Journal of Infectious Diseases 67, no. 4 (2014): 326–328.
A. Meijer, P. Overduin, D. Hommel, Y. van Rijnsoever‐Greven, A. Haenen, and M.‐J. Veldman‐Ariesen, “Outbreak of Respiratory Syncytial Virus Infections in a Nursing Home and Possible Sources of Introduction: The Netherlands, Winter 2012/2013,” Journal of the American Geriatrics Society 61, no. 12 (2013): 2230–2268.
J. L. Y. Yip, S. Kapadia, A. Ahmed, and S. Millership, “Outbreaks of Influenza‐Like Illness in Care Homes in the East of England: Impact of Variations in Neuraminidase Inhibitor Provision,” Public Health 162 (2018): 98–103.
J. Beran, A. Ramirez Villaescusa, R. Devadiga, et al., “Respiratory Syncytial Virus Acute Respiratory Infections in >/= 65‐Year‐Old Adults in Long‐Term Care Facilities in the Czech Republic,” Central European Journal of Public Health 29, no. 3 (2021): 167–176.
M. J. Chasqueira, P. Paixao, M. L. Rodrigues, et al., “Respiratory Infections in Elderly People: Viral Role in a Resident Population of Elderly Care Centers in Lisbon, Winter 2013‐2014,” International Journal of Infectious Diseases 69 (2018): 1–7.
D. S. Hui, J. Woo, E. Hui, et al., “Influenza‐Like Illness in Residential Care Homes: A Study of the Incidence, Aetiological Agents, Natural History and Health Resource Utilisation,” Thorax 63, no. 8 (2008): 690–697.
S. Masse, L. Capai, and A. Falchi, “Epidemiology of Respiratory Pathogens Among Elderly Nursing Home Residents With Acute Respiratory Infections in Corsica, France, 2013‐2017,” BioMed Research International 2017 (2017): 1423718.
T. Ursic, N. G. Miksic, L. Lusa, F. Strle, and M. Petrovec, “Viral Respiratory Infections in a Nursing Home: A Six‐Month Prospective Study,” BMC Infectious Diseases 16, no. 1 (2016): 637.
A. Childs, A. R. Zullo, N. R. Joyce, et al., “The Burden of Respiratory Infections Among Older Adults in Long‐Term Care: A Systematic Review,” BMC Geriatrics 19, no. 1 (2019): 210.
A. R. Falsey and E. E. Walsh, “Respiratory Syncytial Virus Infection in Adults,” Clinical Microbiology Reviews 13, no. 3 (2000): 371–384.
A. R. Falsey, P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh, “Respiratory Syncytial Virus Infection in Elderly and High‐Risk Adults,” New England Journal of Medicine 352, no. 17 (2005): 1749–1759.
K. Korsten, N. Adriaenssens, S. Coenen, et al., “Burden of Respiratory Syncytial Virus Infection in Community‐Dwelling Older Adults in Europe (RESCEU): An International Prospective Cohort Study,” European Respiratory Journal 57, no. 4 (2021): 2002688.
M. H. Rozenbaum, J. Judy, D. Tran, K. Yacisin, S. K. Kurosky, and E. Begier, “Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States,” Infectious Disease and Therapy 12, no. 2 (2023): 677–685.
P. Loubet, N. Lenzi, M. Valette, et al., “Clinical Characteristics and Outcome of Respiratory Syncytial Virus Infection Among Adults Hospitalized With Influenza‐Like Illness in France,” Clinical Microbiology and Infection 23, no. 4 (2017): 253–259.
M. Savic, Y. Penders, T. Shi, A. Branche, and J. Y. Pirçon, “Respiratory Syncytial Virus Disease Burden in Adults Aged 60 Years and Older in High‐Income Countries: A Systematic Literature Review and Meta‐Analysis,” Influenza and Other Respiratory Viruses 17, no. 1 (2023): e13031.
H. Luo, T. Y. Lum, G. H. Wong, J. S. Kwan, J. Y. Tang, and I. Chi, “Predicting Adverse Health Outcomes in Nursing Homes: A 9‐Year Longitudinal Study and Development of the FRAIL‐Minimum Data Set (MDS) Quick Screening Tool,” Journal of the American Medical Directors Association 16, no. 12 (2015): 1042–1047.
X. Zhang, Q. Dou, W. Zhang, et al., “Frailty as a Predictor of all‐Cause Mortality Among Older Nursing Home Residents: A Systematic Review and Meta‐Analysis,” Journal of the American Medical Directors Association 20, no. 6 (2019): 657–663. e4.
M. Reilev, C. Lundby, J. Jensen, S. P. Larsen, H. Hoffmann, and A. Pottegard, “Morbidity and Mortality Among Older People Admitted to Nursing Home,” Age and Ageing 49, no. 1 (2019): 67–73.
E. Walsh, D. Peterson, and A. Falsey, “Risk Factors for Severe Respiratory Syncytial Virus Infection in Elderly Persons,” Journal of Infectious Diseases. 189, no. 2 (2004): 233–238.
A. Njue, W. Nuabor, M. Lyall, et al., “Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High‐Income Countries,” Open Forum Infectious Diseases 10, no. 11 (2023): ofad513.
M. H. Rozenbaum, E. Begier, S. K. Kurosky, et al., “Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data,” Infectious Disease and Therapy 12, no. 6 (2023): 1487–1504.
J. Wise, “First RSV Vaccine for Older Adults Is Approved in Europe,” BMJ 381 (2023): p978.
M. Melgar, A. Britton, L. E. Roper, et al., “Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023,” Morbidity and Mortality Weekly Report 72, no. 29 (2023): 793–801.
K. Kingwell, “RSV Vaccines Score Landmark FDA Approvals,” Nature Reviews. Drug Discovery 22 (2023): 523–525.